Nubain, Nalbuphine

Nubain, Nalbuphine Newswire

Comprehensive Real-Time News Feed for Nubain, Nalbuphine (generic).

Results 1 - 20 of 22 in Nubain, Nalbuphine (generic)

  1. Trevi Therapeutics Selected to Exhibit Poster at 2014 Annual Meeting...Read the original story

    Wednesday Sep 17 | Hispanic Business

    This rigorous study characterized the pharmacokinetics of Nalbuphine ER in renally impaired patients, established that the drug was well tolerated across the entire dose range, and demonstrated the drug is not affected by the dialysis process. We also observed compelling proof-of-concept data in the reduction of itching over the two-week period in the hemodialysis patients.

    Comment?

  2. Trevi Therapeutics Selected To Exhibit Poster At 2014 Annual Meeting Of TheRead the original story

    Tuesday Sep 9 | BioSpace

    Trevi Therapeutics, Inc. , a late-stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, was selected to exhibit a poster at the 2014 Annual Meeting of the American College of Clinical Pharmacology, which takes place September 14th - 16th at the Westin Peachtree Plaza and AmericasMart in Atlanta, GA.

    Comment?

  3. Trevi Therapeutics Selected To Exhibit Poster At 2014 Annual Meeting of theRead the original story

    Tuesday Sep 9 | BioSpace

    Title of Abstract: Pharmacokinetics of Nalbuphine Hydrochloride Extended Release Tablets in Hemodialysis and Healthy Subjects following Multiple Escalating Oral Doses New Haven, CT, September 9, 2014 - Trevi Therapeutics, Inc. , a late-stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, was selected to exhibit a poster at the 2014 Annual Meeting of the American College of Clinical Pharmacology, which takes place September 14th - 16th at the Westin Peachtree Plaza and AmericasMart in Atlanta, GA.

    Comment?

  4. Trevi Therapeutics Selected to Exhibit Poster at 2014 Annual Meeting...Read the original story

    Tuesday Sep 9 | Hispanic Business

    The poster's first author, , MD, Trevi's co-founder and Chief Medical Officer, said, 'Opioids have not historically been well characterized in renally impaired patients. This rigorous study characterized the pharmacokinetics of Nalbuphine ER in renally impaired patients, established that the drug was well tolerated across the entire dose range, and demonstrated the drug is not affected by the dialysis process.

    Comment?

  5. Ex-BSP asset caught making billsRead the original story w/Photo

    Sunday Sep 7 | Sun-Star

    POLICE arrested one man suspected of making fake money and confiscated some P10,000 worth of bills from him in Barangay Day-as, Cebu City yesterday dawn. City Intelligence Branch Chief Romeo Santander said that his team caught Nicolas Herrera, 54; Philip Erasmo, 41; and Maria Cielo Caballes, 30, after they saw the three allegedly cutting fake bills at 1 a.m. It was the third time this year the police arrested Herrera, whose former job was helping the central bank monitor the manufacturer of fake currency.

    Comment?

  6. Narcan antidote to be offered by CVSRead the original story w/Photo

    Wednesday Aug 27 | Examiner.com

    CVS Caremark will soon offer Narcan , an antidote for opioid overdoses such as heroin, Oxycotin, morphine as well as others drugs in this class of narcotic analgesics.

    Comment?

  7. Trevi Therapeutics Announces the Issuance of Two Patents Covering the ...Read the original story

    Aug 20, 2014 | Hispanic Business

    "), a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, announced that it has received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine.

    Comment?

  8. Trevi Therapeutics Announces The Issuance Of Two Patents Covering The ...Read the original story

    Aug 14, 2014 | BioSpace

    Trevi Therapeutics, Inc. , a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced that it has received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine.

    Comment?

  9. Trevi Therapeutics Announces the Issuance of Two Patents Covering the ...Read the original story

    Aug 14, 2014 | Business Wire

    Trevi Therapeutics, Inc. , a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced that it has received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine.

    Comment?

  10. P2M worth of unprescribed meds seizedRead the original story w/Photo

    Aug 13, 2014 | ABS-CBN News

    Authorities seized more than P2 million worth of unprescribed medicines such as Valium , Cytotec, and Nubain in a buy-bust operation at Tacay Road, Baguio City Wednesday afternoon.

    Comment?

  11. Teen guarded P6M in shabuRead the original story

    Aug 10, 2014 | Sun-Star

    A 14-YEAR-OLD girl believed to have been used as a drug mule was arrested by police, who confiscated from her an estimated P5.9 million worth of shabu in Labangon, Cebu City last Saturday night.

    Comment?

  12. Trevi Therapeutics Announces Initiation of a Pivotal Study of Nalbuphine ER in Uremic PruritusRead the original story

    Jul 14, 2014 | Hispanic Business

    The Company recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was well tolerated in hemodialysis patients and established proof-of-concept for Nalbuphine ER in treating uremic pruritus.

    Comment?

  13. Trevi Therapeutics Announces Initiation of a Pivotal Study of Nalbuphine ER in Uremic PruritusRead the original story

    Jul 14, 2014 | Business Wire

    Trevi Therapeutics, Inc. , a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced the first patient enrolled in the pivotal study of Nalbuphine ER in hemodialysis patients with uremic pruritus .

    Comment?

  14. Boost drive against illegal drugs or face...Read the original story

    Jul 7, 2014 | Sun-Star

    THE Cebu Provincial Police Office is assessing the performance of all police station chiefs in the campaign against illegal drugs.

    Comment?

  15. Trevi Therapeutics Announces $25 Million Series B Financing Led by...Read the original story

    Jun 11, 2014 | Hispanic Business

    " or the "Company"), a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, announced a Series B financing of ).

    Comment?

  16. Trevi Therapeutics Reports $25 Million Series B Financing Led by TPG BiotechRead the original story

    Jun 9, 2014 | Hispanic Business

    The Company plans to use the funding for the initiation of pivotal trials in two severe itch conditions: uremic pruritus and prurigo nodularis.

    Comment?

  17. Clinical Stage Biotech Trevi Therapeutics Brings In $25 Million Series B FinancingRead the original story

    Jun 4, 2014 | BioSpace

    Trevi Therapeutics Announces $25 Million Series B Financing Led by TPG Biotech for Development of Nalbuphine ER NEW HAVEN, Conn.-- --Trevi Therapeutics, Inc. , a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced a Series B financing of $25 million led by TPG Biotech, the life science ... (more)

    Comment?

  18. TPG Biotech leads Series B round for TreviRead the original story w/Photo

    Jun 4, 2014 | PE Hub

    Trevi Therapeutics said Wednesday that it has received $25 million in Series B financing.

    Comment?

  19. Trevi Therapeutics Announces $25 Million Series B Financing Led by...Read the original story

    Jun 3, 2014 | Venture Capital Access Online

    Trevi Therapeutics, Inc. , a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced a Series B financing of $25 million led by TPG Biotech, the life science venture investment arm of TPG, with $15 million funded at first closing.

    Comment?

  20. Trevi Therapeutics Exhibits Poster at 2014 Annual Meeting of the...Read the original story

    May 21, 2014 | Hispanic Business

    Nalbuphine ER was dose escalated every three days from 30 mg to 240 mg BID over 17 days.

    Comment?